BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...to isolate and expand. Newcos including GentiBio Inc., Kyverna Therapeutics Inc. and Sonoma Biotherapeutics emerged...
BioCentury | Dec 10, 2020
Management Tracks

Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird

...to the board of directors at Gilead Sciences Inc. (NASDAQ:GILD). Bluestone is the president and CEO of Sonoma Biotherapeutics...
...CSO at Akorn Inc. (NASDAQ:AKRX). Danielle Golovin Gilead Sciences Inc. Robert W. Baird Phagelux Inc. Chiesi Farmaceutici S.p.A. Oyster Point Pharma Inc. Sonoma Biotherapeutics Cellular...
BioCentury | Oct 1, 2020
Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

...and Abbott Laboratories (NYSE:ABT) that included leadership roles in immuno-oncology and immunology drug discovery. Karen Tkach Tuzman Sonoma Biotherapeutics Lyell...
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

...other Treg-focused newcos have launched this year. Sonoma Biotherapeutics...
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

...biopharmas and other key players. Two newcos have launched since the start of the year. Sonoma Biotherapeutics...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

...Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics...
...and inflammatory conditions using technology gained through its 2018 acquisition of TxCell S.A. COMPANY PROFILE Sonoma Biotherapeutics...
Items per page:
1 - 6 of 6
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...to isolate and expand. Newcos including GentiBio Inc., Kyverna Therapeutics Inc. and Sonoma Biotherapeutics emerged...
BioCentury | Dec 10, 2020
Management Tracks

Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird

...to the board of directors at Gilead Sciences Inc. (NASDAQ:GILD). Bluestone is the president and CEO of Sonoma Biotherapeutics...
...CSO at Akorn Inc. (NASDAQ:AKRX). Danielle Golovin Gilead Sciences Inc. Robert W. Baird Phagelux Inc. Chiesi Farmaceutici S.p.A. Oyster Point Pharma Inc. Sonoma Biotherapeutics Cellular...
BioCentury | Oct 1, 2020
Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

...and Abbott Laboratories (NYSE:ABT) that included leadership roles in immuno-oncology and immunology drug discovery. Karen Tkach Tuzman Sonoma Biotherapeutics Lyell...
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

...other Treg-focused newcos have launched this year. Sonoma Biotherapeutics...
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

...biopharmas and other key players. Two newcos have launched since the start of the year. Sonoma Biotherapeutics...
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

...Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics...
...and inflammatory conditions using technology gained through its 2018 acquisition of TxCell S.A. COMPANY PROFILE Sonoma Biotherapeutics...
Items per page:
1 - 6 of 6